Epitope-specific humoral responses to human cytomegalovirus glycoprotein-B vaccine with MF59: Anti-AD2 levels correlate with protection from viremia
The human cytomegalovirus (HCMV) virion envelope protein glycoprotein B (gB) is essential for viral entry and represents a major target for humoral responses following infection. Previously, a phase-2 placebo-controlled clinical trial conducted in solid organ transplant candidates demonstrated that...
Main Authors: | Baraniak, Ilona, Kropff, Barbara, McLean, Gary R., Pichon, Sylvie, Piras-Douce, Fabienne, Milne, Richard S. B., Smith, Colette, Mach, Michael, Griffiths, Paul D., Reeves, Matthew B. |
---|---|
Format: | Article |
Language: | English |
Published: |
Oxford University Press for the Infectious Diseases Society of America
2018
|
Subjects: | |
Online Access: | https://repository.londonmet.ac.uk/1376/1/JID_2018_correctedproof.pdf |
Similar Items
-
Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies
by: Baraniak, Ilona, et al.
Published: (2018) -
IgA binds to the AD-2 epitope of glycoprotein B and neutralizes human cytomegalovirus
by: Siddiqui, Saima, et al.
Published: (2020) -
Seronegative patients vaccinated with cytomegalovirus gB-MF59 vaccine have evidence of neutralising antibody responses against gB early post-transplantation
by: Ilona Baraniak, et al.
Published: (2019-12-01) -
A temperature-dependent virus-binding assay reveals the presence of neutralising antibodies in human cytomegalovirus gB vaccine recipients’ sera
by: Gomes, Ariane, et al.
Published: (2023) -
Human cytomegalovirus vaccination: progress and perspectives of recombinant gB
by: Manghera, Avneet, et al.
Published: (2016)